Galactan induces macrophage M0 to M1 conversion to combat colon cancer

被引：2
|
作者：
Meng, Yue [1 ]
Yang, Guang [1 ]
Ren, Ai [1 ]
Qu, Yunhe [1 ]
Wang, Xue [1 ]
Mayo, Kevin H. [2 ]
Zhou, Yifa [1 ]
Song, Chengcheng [1 ]
机构：
[1] Northeast Normal Univ, Engn Res Ctr Glycoconjugates, Sch Life Sci,Minist Educ, Jilin Prov Key Lab Chem & Biol Changbai Mt Nat Dru, Changchun 130024, Peoples R China
[2] Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall, Minneapolis, MN 55455 USA
来源：
FOOD SCIENCE AND TECHNOLOGY RESEARCH | 2024年 / 30卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Cantharellus cibarius; galactan; macrophages; antitumor effect; TUMOR-ASSOCIATED MACROPHAGES; STRUCTURAL-CHARACTERIZATION; IMMUNOMODULATORY ACTIVITY; CELLS; ACTIVATION; MECHANISMS; PHENOTYPE;
D O I：
10.3136/fstr.FSTR-D-23-00039
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
A 3-O-methylated-galactan WCCP-N-b from Cantharellus cibarius polarizes RAW264.7 macrophages, bone marrow -derived macrophages (BMDMs), and peritoneal macrophages (PEMs) leading to enhanced secretion of cytokine TNF-alpha and subsequent cytotoxic effects on HCT116 and CT26 colon cancer cells. Investigation into the mechanism of action suggests that WCCP-N-b polarizes macrophages by targeting Toll -like receptor 2 and activation of MAPKs and NF -KB signaling pathways. Overall, our results indicate that this linear 3-O-methylated-galactan inhibits colon cancer cells via conversion of M0 to M1 macrophages.
引用
收藏
页码：75 / 82
页数：9
相关论文
共 50 条
  • [31] Erythrocyte aggregation determined with the Myrenne aggregometer at two modes (M0, M1) and at two times (5 and 10 sec)
    Vayá, A
    Falcó, C
    Fernández, P
    Contreras, T
    Valls, M
    Aznar, J
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2003, 29 (02) : 119 - 127
  • [32] OXIDANT STRESS MAY CONTRIBUTE TO MACROPHAGE (M0) DYSFUNCTION FOLLOWING ERYTHROPHAGOCYTOSIS
    LOEGERING, DJ
    EATON, JW
    BLOOD, 1993, 82 (10) : A28 - A28
  • [33] Development of a Prognostic Risk Model for Esophageal Cancer Based on M0 Macrophage-Related Genes
    Zuo, Xiaoping
    Wang, Fuqiang
    Liu, Guofeng
    Xie, Shenglong
    Deng, Senyi
    Wang, Yun
    ONCOTARGETS AND THERAPY, 2024, 17 : 1209 - 1222
  • [34] Exosomes derived from M0, M1 and M2 macrophages exert distinct influences on the proliferation and differentiation of mesenchymal stem cells
    Xia, Yu
    He, Xiao-Tao
    Xu, Xin-Yue
    Tian, Bei-Min
    An, Ying
    Chen, Fa-Ming
    PEERJ, 2020, 8
  • [35] A Comparative Study of Segmentation Method for Computer-aided Diagnosis (CAD) Leukemia AML Subtype M0, M1, and M2
    Wiharto
    Widiarto, Wisnu
    Suryani, Esti
    Hidayatullah, Nurmajid
    INTERNATIONAL JOURNAL OF ADVANCED COMPUTER SCIENCE AND APPLICATIONS, 2021, 12 (11) : 585 - 593
  • [36] Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression
    Yuan, Ang
    Hsiao, Yi-Jing
    Chen, Hsuan-Yu
    Chen, Huei-Wen
    Ho, Chao-Chi
    Chen, Yu-Yun
    Liu, Yi-Chia
    Hong, Tsai-Hsia
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Yang, Pan-Chyr
    SCIENTIFIC REPORTS, 2015, 5
  • [37] Opposite Effects of M1 and M2 Macrophage Subtypes on Lung Cancer Progression
    Ang Yuan
    Yi-Jing Hsiao
    Hsuan-Yu Chen
    Huei-Wen Chen
    Chao-Chi Ho
    Yu-Yun Chen
    Yi-Chia Liu
    Tsai-Hsia Hong
    Sung-Liang Yu
    Jeremy J.W. Chen
    Pan-Chyr Yang
    Scientific Reports, 5
  • [38] ETOPOSIDE ALONE AND IN COMBINATION WITH CYCLOPHOSPHAMIDE, ADRIAMYCIN AND CIS-PLATINUM IN PATIENTS WITH M0 AND M1 NON-SMALL-CELL LUNG-CANCER
    EAGAN, RT
    CANCER TREATMENT REVIEWS, 1982, 9 : 119 - 131
  • [39] Utility of PET-Radiomics in Stratifying EGFR Mutation in Non-Small Cell Lung Cancer Patients with Subgroups of M0 and M1 Stages
    Tran, V. T. .
    Tu, S. J.
    MEDICAL PHYSICS, 2024, 51 (10) : 7725 - 7726
  • [40] Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients
    Oliver, RTD
    Lee, A
    Farrugia, D
    Ansell, W
    BRITISH JOURNAL OF CANCER, 2001, 85 : 88 - 88
12345